An update on the pharmacotherapy of neovascular age-related macular degeneration.
about
Treatment of Exudative Age-related Macular Degeneration: Focus on AfliberceptPharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbitsSingle ocular injection of a sustained-release anti-VEGF delivers 6months pharmacokinetics and efficacy in a primate laser CNV modelFundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseasesDeletion of miR-150 Exacerbates Retinal Vascular Overgrowth in High-Fat-Diet Induced Diabetic Mice.Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept.Superoxide dismutase1 levels in North Indian population with age-related macular degeneration.Osteonecrosis of the jaw associated with ziv-afliberceptComparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and AfliberceptMechanisms of age-related macular degeneration and therapeutic opportunities.Current choice of treatments for neovascular AMD.Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register.Current advances in the treatment of neovascular age-related macular degeneration.Focus Groups in Elderly Ophthalmologic Patients: Setting the Stage for Quantitative Preference Elicitation.TGF-β participates choroid neovascularization through Smad2/3-VEGF/TNF-α signaling in mice with Laser-induced wet age-related macular degeneration.One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD.Bevacizumab for choroidal neovascularisation in enhanced S-cone syndrome.Aflibercept for inflammatory choroidal neovascularization with persistent fluid on intravitreal ranibizumab therapy.Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration.
P2860
Q26786766-87610603-1CDA-472F-9512-C883F6E3533CQ28538492-FA58F281-26E1-4F61-9C1D-B336FAD9B900Q32172336-69F1ABD3-DE6E-448B-B72B-282FBBBB1F62Q33840787-E4395A87-A398-4C29-824D-65931413CC16Q36053089-80BD9DE0-40F8-4F59-8C72-1F86A3627F07Q36674580-D88BEC0D-5E15-4333-B279-54C205D556E9Q37394541-CDA686D6-45E6-463C-9935-367BB0D11B16Q37525339-8A882155-193E-4594-ACF5-9327DE4A234AQ37681931-82F39412-93E8-4ACC-82D2-7A726857AA99Q38150757-8CB81CB9-5687-4DA1-802A-7BE4F36CAB92Q38285319-E763F3DD-E6E4-4BDC-BF6D-D78EC2FFD0B7Q38611703-009A6EDE-B852-406E-9684-9BAF69427130Q38902191-718DFB10-7CBD-4DD7-99DE-798885F28F06Q41334925-9DD7892C-E986-4B48-BF26-A4DCE5A2CC07Q41550102-E7D3444F-6D7F-443A-A229-12B74D970651Q43764405-1984472B-EBC3-4680-B5A2-DEEC371291A2Q51637209-CED46E8B-B59C-4369-B722-A024DD367742Q54355688-1F7518AC-B04E-4DF2-95F0-3AF7451A3BA4Q55474642-16E423B0-4995-4084-B7D4-7C04DEC04314
P2860
An update on the pharmacotherapy of neovascular age-related macular degeneration.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
An update on the pharmacotherapy of neovascular age-related macular degeneration.
@en
type
label
An update on the pharmacotherapy of neovascular age-related macular degeneration.
@en
prefLabel
An update on the pharmacotherapy of neovascular age-related macular degeneration.
@en
P2860
P1476
An update on the pharmacotherapy of neovascular age-related macular degeneration
@en
P2093
Roberto Gallego-Pinazo
Sarah Mrejen
P2860
P304
P356
10.1517/14656566.2013.787410
P407
P577
2013-04-08T00:00:00Z